Biological Affinity Driven Antibody Drug

Targeted therapy, which first became available in the late 1990s, has had a significant impact on the treatment of cancer. Currently, because of advancement in the field of technology, various types of therapies are discovered to treat cancer. In this essay, targeted therapy is defined as a therapy in which various drugs or other substances are used to recognize and kill the cancerous cells without harming the normal cell (National cancer institute, 2014). Effectiveness refers to the degree in

It has broad variety of anti-tumor activity and forms the backbone of combination chemotherapy regimes presently

Some of traditional drugs may be effective in patients whose cancers have a specific molecular target, and not for other patients. To solve this problem of patient-specificity, pharmaceutical research have seen the expansion of individually tailored cancer treatment, which is an application of targeted therapy, and this is where biopharmaceuticals are. As an increasing part of the population is diagnosed with cancer and as these patients live longer, increasing care will be given to patients who have received these drugs. Moreover, in the case of cancer therapy, those drugs and especially with mABs are a promise of less side effects : recombinant DNA technology makes it possible to genetically engineer an antibody to reduce the risk of host immune response.

Many doctors, physicians, researchers and biotech companies--including the revolutionary Seattle Genetics research facility--are now turning to antibody-assisted cancer treatments and precisely targeted cures instead of treating cancer with a cocktail of chemicals and radiation that generate risky side effects and damage the healthy tissue that patients need to recover. Cancers are among the most frightening and difficult-to-treat illnesses. Ranked as the leading cause of death and disability, cancer is actually an umbrella term that covers many different diseases. Each person faces a unique disease because cancers interact with the body's existing cells, so each case has a

A team from the Brazilian university says the experimental drug binds with tumor cells and causes the loss of key molecules.

With the use of our ever-growing genetic understanding, we are rapidly moving towards personalised cancer treatment. The availability and affordability of technologies allowing us to gain a comprehensive molecular characterisation of tumours and one’s own genetic make-up, brings personalised medicine right into the forefront of cancer treatment. Personalised medicine promises to be a potentially revolutionary new form of cancer treatment, with the use of indicators such as discrete genes and proteins to differentiate one cancer type form another and enable the use of targeted therapies. Throughout this project I explore exactly what personalised medicine is and investigate the opportunities and challenges that accompany its potential to be next new form of cancer treatment.

Immunotherapy for cancer treatment has had tremendous growth recently with increased awareness and knowledge of the immune system and potential means to manipulate it for therapeutic intent. Progress in the treatment of viral infections including CMV, EBV, HHV-6, utilization of immune checkpoint blockade for melanoma, non-small cell lung cancer, and Hodgkin Lymphoma, as well as rapid emergence of genetically modified T cells against CD19+ B cells have contributed to the growth in this area.Antibody-targeted therapy has now become standard of care for many malignancies, and the multi-domain utilization of antigen-specific adoptive T-cell therapy has shown great promises. 4 While our understanding of B cell and T cell and our ability to

In the past, most of the cancer drugs were developed to hinder the growth of tumors. The main strategy was so called “targeted therapies, which interfere with genetic signals that act like accelerators, causing tumors to grow.”1 However, because there are too many pathways and signals that can act as an accelerator of the cancer growth, a single drug was usually not enough to suppress the cancer.

To create the best version of virotherapy, scientists are discovering two ways to be confident the viruses hit target cells with no other harm to other cells. One strategy virotherapy researchers are exploring is called transductional targeting. With this form of targeting cancer cells, researchers are modifying the viruses used so they are only attracted to only cancerous cells to contaminate them. To prevent the viruses from entering normal cells, transductional targeting works by binding “adapter” molecules onto the antibodies, proteins on the outside of virus, or tweaking the antibodies so that they will not allow viruses to enter normal cells and rather let them gain up on tumor cells. The second strategy discussed in the article is named transcriptional targeting. The goal of this form of targeting is to modify the viruses

This review will provide a brief investigation of current cancer therapies and the lack of effectiveness that these treatments provide while treating the disease. The aim of this review is to discuss the urgent need to develop new and effective cancer therapy options that can bridge the gap between the various types of cancer and effective cancer targeting.

As a result, recent molecular and translational research is introducing target-based therapies for the management of

Second generation Antibody-drug conjugate consider as a new approach for treatments of TNBC. The main idea is to use an antibody and cytotoxic agents together to produce a synergistic effect and to ensure delivery of the cytotoxic agent to the target cell (6) Our main goal in this research is to develop a novel antibody based therapy against LRP8. We hypothesis that an anti-LRP8 antibody conjugated to cytotoxic drug will lead toward effective therapy for TNBC. We will perform experiments using flow cytometry and confocal microscopy to prove that LRP8 is suitable ADC target. Two main factors will contribute to whether it is suitable target:

Cancer is very complex and different throughout every person. Throughout the years there has been advancements in science and technology toward a more personalized approach, trying to understand the causes and treatments best for each patient’s cancer. Through the launch of Precision Medicine Initiative researchers, doctors, pharmaceutical companies, government agencies and more will come together in the efforts of introducing personalized medicine.

Targeted Therapy: The method uses drugs along with other agents (including monoclonal antibodies). These antibodies attach to specific parts of the cancerous cells to enable treatment targeting with radiation, drugs, or by obstructing the growth of cancerous cells.

Unlike Gilead that has only one product in its Oncology line, Bristol-Myers Squibb presently have four different drugs namely: Erbitux –an epidermal growth factor receptor (EGFR) antagonist for the treatment of Head & Neck cancer and Colorectal cancer,(2) Opdivo (nivolumab) for the treatment of unresectable or metastic melanoma and lungs cancer, (3) Syrcel( dasatinb) for the treatment of newly diagnosed adult with Philadelphia chromosome –positive (ph+) chronic myeloid leukemia and (4) Yervoy (ipilimumob) for the treatment of melanoma a type of skin cancer that spread and as such cannot be remove by surgery. Like Seattle Genetics, the company products use either Antibody-drug Conjugate (ADC) though in a different version by linking potent cytotoxic to monoclonal antibodies targeted to specific tumor cells or immune-oncology, an innovative technology that unlocks the body own immune system to fight against cancerous cells. It also expanded its focus to Nolch inhibitor (used in blocking powerful pathway that promotes tumor cell survival for certain other types of cancer. (Bristol-Myer Squibb, 2014) Because the technology is similar but used differently, BMS would be considered a close competitor who currently has the advantage of having four targeted specific drugs and 12 other oncology and immune-oncology in various trial phases.